Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K. Alderuccio JP, et al. Among authors: collins gp. Blood Adv. 2021 Jul 27;5(14):2852-2862. doi: 10.1182/bloodadvances.2021004458. Blood Adv. 2021. PMID: 34283175 Free PMC article.
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA, Linton KM, Rohman P, Kothari J, Cwynarski K, Ardeshna K, Bailey C, Osborne WL, Rowntree C, Eden D, Shankara P, Eyre DW, Jasani P, Chaidos A, Collins GP, Hatton CS. Eyre TA, et al. Among authors: collins gp. Br J Haematol. 2016 Jun;173(6):896-904. doi: 10.1111/bjh.14021. Epub 2016 Mar 9. Br J Haematol. 2016. PMID: 26956150 Free article.
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Noy A, et al. Among authors: collins gp. Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. Blood. 2017. PMID: 28167659 Free PMC article. Clinical Trial.
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP. Eyre TA, et al. Among authors: collins gp. Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. Br J Haematol. 2018. PMID: 28342183 Free article. Clinical Trial. No abstract available.
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP. Eyre TA, et al. Among authors: collins gp. Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. Epub 2017 Aug 31. Br J Haematol. 2017. PMID: 28857136 Free article.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP. Eyre TA, et al. Among authors: collins gp. Hematol Oncol. 2019 Oct;37(4):352-359. doi: 10.1002/hon.2662. Epub 2019 Sep 9. Hematol Oncol. 2019. PMID: 31385336 Clinical Trial.
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Booth S, Plaschkes H, Kirkwood AA, Gibb A, Horgan P, Higham C, Oladipo JM, Browning J, Khan U, Tseu B, Chen L, Willan J, Wolf J, Gunawan A, Fields P, Ebsworth T, Lown R, Gordon-Walker D, Shah N, Linton KM, Collins GP, Kothari J, Hildyard C, Eyre TA. Booth S, et al. Among authors: collins gp. Blood Adv. 2020 Sep 22;4(18):4337-4346. doi: 10.1182/bloodadvances.2020002553. Blood Adv. 2020. PMID: 32915975 Free PMC article.
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, Morschhauser F, Collins GP, Ma S, Peles S, Smith SD, Barrientos JC, Chong E, Wu S, Cheung LW, Kwei K, Hauns B, Arango-Hisijara I, Chen R. Noy A, et al. Among authors: collins gp. Blood Adv. 2020 Nov 24;4(22):5773-5784. doi: 10.1182/bloodadvances.2020003121. Blood Adv. 2020. PMID: 33227125 Free PMC article. Clinical Trial.
196 results